Schrödinger will Transform Drug Discovery with 24% Growth

Schrödinger stands at the confluence of biotechnology, materials science, and enterprise software, pioneering a transformation in the field of molecular discovery. The company has moved beyond the traditional silos of either a software provider or a drug developer to create a hybrid enterprise. Leveraging a proprietary, physics-based computational platform refined over three decades, Schrödinger aims to industrialize the process of discovering novel, high-quality molecules, fundamentally altering the economics and timelines of research and development.

The investment opportunity in Schrödinger is rooted in the immense inefficiencies of traditional drug discovery—a process burdened by exorbitant costs, protracted timelines, and staggeringly high failure rates. Schrödinger addresses this challenge with a synergistic three-pillar business model designed to create and capture value across the discovery spectrum. The foundation is a high-margin Software Licensing business, which provides stable, recurring revenue from a blue-chip customer base that includes all top-20 pharmaceutical companies. This recurring revenue engine funds the company’s R&D efforts. The second pillar consists of strategic Drug Discovery Collaborations, which serve as a powerful validation engine for the platform. These partnerships generate non-dilutive capital through upfront payments, milestones, and royalties, de-risking the technology with external capital; as of December 31, 2023, the company maintained 19 active collaborative programs. The third and highest-upside pillar is the Proprietary Drug Pipeline, where Schrödinger retains the full economic potential of its discoveries by advancing its own therapeutic assets, such as SGR-1505 and SGR-3515. The bull case for Schrödinger is built on this durable business architecture and the platform's extensive validation, demonstrated by its contribution to FDA-approved drugs (TIBSOVO®, IDHIFA®) and its role in several high-value industry transactions (e.g., Nimbus/Takeda, Morphic/Lilly). A recent and crucial strategic pivot toward financial discipline, marked by guidance for lower operating expenses in 2025, signals a mature approach to capital allocation that de-risks the investment thesis by prioritizing a sustainable path to profitability and extending the company's financial runway.

--------------------------------------------------------------------------------

Part 1: Universal Checklist (Buffett/Munger Principles)

To deconstruct Schrödinger's fundamental quality as a long-term investment, this section applies the time-tested principles of value investing. The analysis focuses on the four critical pillars identified by investors like Warren Buffett and Charlie Munger: the quality and integrity of leadership, the resilience and competitive strength of the business itself, the company's future growth prospects, and finally, the relationship between its market price and intrinsic value.

1. Leadership & Integrity

A skilled and aligned management team is the cornerstone of any durable enterprise. Schrödinger is led by a team that blends deep scientific acumen with seasoned commercial and financial experience, a critical combination for its hybrid business model.

• Leadership Expertise and Track Record:

    ◦ Ramy Farid, Ph.D. (President & CEO): Dr. Farid's long tenure with the company ensures a deep, continuous understanding of the technology and its strategic evolution.

    ◦ Karen Akinsanya, Ph.D. (President of R&D, Therapeutics): Dr. Akinsanya is instrumental in applying the company's platform to advance its high-value proprietary drug discovery pipeline.

    ◦ Margaret Dugan, M.D. (Chief Medical Officer): As a board-certified medical oncologist and hematologist with senior leadership experience at global pharmaceutical companies like Novartis and Dracen, Dr. Dugan brings critical clinical development expertise.

    ◦ Richard Friesner, Ph.D. (Co-founder, Director, Consultant): A key architect of the company's foundational technology, Dr. Friesner remains deeply involved through his board role and a consulting agreement, for which he was paid $420,000 in 2023.

    ◦ Board Expertise: The board includes directors with extensive industry experience, such as Jeffrey Chodakewitz, M.D., a former senior executive at Merck, and Gary Sender, who has held CFO roles at multiple biopharmaceutical companies including Nabriva, Shire, and Merck.

• Capital Allocation and Strategic Discipline: Management has demonstrated a capacity for both investing for growth and adapting to market conditions. From 2018 to 2023, the company invested a cumulative $486 million in R&D. This investment has yielded tangible returns, including $163 million in drug discovery revenue, $165 million in cash distributions from equity stakes, and $91 million in realized and unrealized equity value during the same period. More recently, management has initiated a strategic pivot toward financial discipline, providing 2025 guidance for operating expenses to be lower than in 2024 and cash used in operating activities to be "significantly lower." This prudent move balances the high cash burn of clinical development with the stability of the software business, protecting shareholder value in the face of potential clinical setbacks. Strategic investments, such as the 2022 acquisition of XTAL BioStructures, have also been targeted to augment internal capabilities, enhancing the company's ability to produce high-quality protein structures for its discovery programs.

• Integrity and Shareholder Alignment: Schrödinger operates with robust governance structures, including a formal code of business conduct, an insider trading policy based on Rule 10b5-1, and a clawback policy for executive compensation. Shareholder alignment is further evidenced by the significant ownership stakes held by sophisticated, long-term investors. As of April 22, 2024, the Bill & Melinda Gates Foundation Trust held a 22.2% stake, and as of January 23, 2024, Blackrock held 13.8%, providing a strong vote of confidence in the company's long-term strategy and governance.

The leadership team's blend of scientific depth and commercial savvy, coupled with an increasingly disciplined approach to capital allocation and strong alignment with long-term shareholders, provides a solid foundation for the underlying business.

2. Business Quality & Resilience

The strategic importance of Schrödinger's unique business architecture cannot be overstated. It is designed to foster innovation, validate technology, and manage the inherent risks of drug discovery.

• The Synergistic Three-Pillar Model:

    ◦ Software Licensing: This segment serves as the company's high-margin, recurring revenue engine. Its software is an industry-standard tool, licensed by all top 20 pharmaceutical companies, providing stable cash flow that funds ambitious R&D efforts for both the platform and the pipeline.

    ◦ Drug Discovery Collaborations: This is the validation engine. By partnering with leading biopharma companies, Schrödinger proves the value of its platform on external programs, generating non-dilutive capital through upfront fees, milestones, and potential royalties. As of December 31, 2023, there were 19 active collaborative programs, each serving as a testament to the platform's capabilities.

    ◦ Proprietary Pipeline: This is the primary value-creation engine. By using its own platform to discover and develop wholly-owned assets like SGR-1505 (MALT1 inhibitor) and SGR-3515 (Wee1/Myt1 inhibitor), the company retains the full economic upside, transforming technological prowess into potentially life-changing and highly valuable medicines.

• Analysis of the Competitive Moat: Schrödinger's competitive advantages are layered and mutually reinforcing, consistent with Hamilton Helmer's "7 Powers" framework.

    ◦ Process Power: The company's core moat is a superior, more efficient drug discovery process that has generated tangible, monetized value. This process is validated by its contribution to two FDA-approved drugs (TIBSOVO® and IDHIFA®) and by its role in generating assets that led to major transactions, such as the Nimbus/Takeda and Morphic/Lilly deals, which returned over $194 million in direct cash distributions to Schrödinger.

    ◦ Switching Costs: The platform is deeply integrated into the R&D workflows of its customers. Tools like LiveDesign become central to a research team's collaborative process, creating significant friction and cost to switching. This is reflected in exceptional customer retention rates: 92% for customers with over $100k in annual contract value (ACV) and 98% for those with over $500k in ACV in 2023.

    ◦ Branding: With a history spanning over 30 years, Schrödinger has established itself as the premier, scientifically credible brand in the field of computational chemistry, synonymous with rigor and cutting-edge science.

    ◦ Cornered Resource: The company's team of 378 employees with Ph.D.s represents a formidable concentration of specialized, accumulated know-how in physics-based modeling and drug discovery. This intellectual capital, along with proprietary assets like its refined cryo-EM structures, is exceptionally difficult for competitors to replicate.

    ◦ Counter-Positioning: Schrödinger's hybrid software/biotech model makes it a difficult target for direct competition. Traditional pharmaceutical companies possess the drug development expertise but lack the agile software culture and decades of specialized algorithm development. Pure-play tech companies have the software expertise but lack the deep, nuanced understanding of biology, chemistry, and the regulatory pathways required for drug discovery.

    ◦ Network Effects: While not a traditional user-to-user network effect, the platform's adoption as an industry standard by all top 20 pharmaceutical companies creates a powerful ecosystem effect, enhancing its value, data advantage, and status as the default platform.

    ◦ Scale Economies: The platform's use of machine learning suggests that the sheer scale of its computations and the breadth of data from its customer base and internal programs create a virtuous cycle, continuously improving the accuracy and predictive power of its models over time.

• Financial Strength:

Metric

Value/Trend

Source Justification

Balance Sheet

Strong

Cash, equivalents, and marketable securities of $475.2 million (as of Dec 31, 2023). Historically operated with zero net debt.

Revenue Trend

Growing but Fluctuating

Total revenues increased 20% from $181.0M in FY 2022 to $216.7M in FY 2023. Revenue can fluctuate significantly based on collaboration milestones.

Margin Profile

High in Software

Software gross margin was 77% in fiscal year 2023.

Cash Flow

Negative (Improving)

Net cash used in operating activities was $136.7 million in 2023. 2025 guidance projects significantly lower cash use.

Return on Capital

Not Meaningful

Historical operating losses make traditional ROCE an unhelpful metric. Instead, the positive return on R&D investment ($419M in realized value from $486M in R&D spend) is a better proxy for capital efficiency.

• Pricing Power: The company's ability to consistently grow its base of high-value customers—increasing from 18 customers with over $1 million ACV in 2022 to 27 such customers in 2023—demonstrates significant pricing power. As its platform becomes indispensable for accelerating discovery, it commands premium pricing.

• Execution & Track Record: Management has a strong track record of delivering on its strategic goals. The successful execution of the major collaboration with Novartis and the steady advancement of proprietary programs like SGR-1505 and SGR-3515 into clinical trials serve as clear evidence of the team's ability to execute complex scientific and business objectives.

The company's robust business model and multi-faceted competitive moat create a resilient enterprise, well-positioned to capitalize on its significant future growth opportunities.

3. Future Prospects & Catalysts

Schrödinger has a dense pipeline of potential value-inflection points over the near-to-mid term, driven by progress in both its proprietary programs and its underlying platform technology.

1. SGR-1505 (MALT1 inhibitor): The presentation of initial clinical data from the Phase 1 study in patients with B-cell malignancies represents a major upcoming catalyst that will provide the first human proof-of-concept for a wholly-owned Schrödinger asset.

2. SGR-3515 (Wee1/Myt1 inhibitor): Initial Phase 1 clinical data for this program, targeting patients with advanced solid tumors, is expected in the fourth quarter of 2025. Positive data would further validate the pipeline and the platform's ability to generate differentiated molecules.

3. Collaborations: The potential for new, large-scale collaborations similar to the Novartis deal, and the achievement of development and commercial milestones from existing partnerships with industry leaders like Bristol-Myers Squibb, Lilly, and Otsuka could provide significant non-dilutive funding.

4. Platform Expansion: Continued customer adoption of the core platform, particularly the scaling of new solutions like the predictive toxicology offering, will drive growth in the high-margin software business.

• Total Addressable Market (TAM) and Growth Runway: Schrödinger operates in the massive global drug discovery and materials science industries. The company's oncology pipeline, a key value driver, is focused on innovative approaches like synthetic lethality, which aims to address the vast "untapped space" of cancer lesions (approximately 71%) that are not addressable with today's precision oncology drugs. This highlights the enormous runway for growth and medical impact.

• A Sober Assessment of Risk: It is crucial to acknowledge the inherent risks of drug development. The discontinuation of the SGR-2921 program, despite promising preclinical data, serves as a clear and tangible reminder that a superior discovery platform does not eliminate biological and clinical safety risks. This event reinforces that the platform's primary value is in its ability to generate a greater number of higher-quality "shots on goal," rather than guaranteeing that every shot will be successful. Probabilities of success must remain conservative.

The company's future is defined by a rich set of potential catalysts, but this potential must be weighed against the fundamental risks of clinical development, leading to the critical question of valuation.

4. The Final Decision: Price vs. Value

A conservative valuation of Schrödinger is best framed using a Sum-of-the-Parts (SOTP) approach, which analyzes the primary components of the business separately to build a picture of intrinsic worth.

• Software Business: This segment can be valued as a stable, high-margin, growing enterprise software business with a sticky customer base and a strong competitive moat.

• Cash Position: The company maintains a strong balance sheet with $475.2 million in cash, equivalents, and marketable securities as of December 31, 2023, and no net debt.

• Drug Discovery Pipeline: This represents a portfolio of high-risk, high-reward assets. Its value is more speculative and dependent on future clinical data, but it offers substantial upside potential.

• Price vs. Conservative Value Estimate: As of early January 2024, Schrödinger's market capitalization was approximately $2.3 billion. A conservative analysis suggests that a significant portion of this market value is supported by the combination of its net cash position and a reasonable valuation of its durable, high-margin software business. This implies that an investor at the $2.3 billion valuation is potentially acquiring the entire portfolio of partnered and proprietary drug candidates—including the clinical-stage assets SGR-1505 and SGR-3515—for a deeply discounted price, creating a compelling margin of safety against future clinical trial failures.

The application of these core value investing principles suggests Schrödinger is a high-quality enterprise with strong leadership, a defensible moat, and a clear path to future growth, available at a potentially attractive valuation.

--------------------------------------------------------------------------------

Part 2: Specialized High-Growth & "100-Bagger" Filter (Lynch/Mayer Principles)

Beyond the classic value investing framework, this section evaluates Schrödinger through the lens of a high-growth, venture-style investment. It assesses characteristics common to innovative companies that have generated extraordinary long-term returns, as described by investors like Peter Lynch and Chris Mayer.

• Pursuit of a "Hard Path" Technology: Schrödinger has dedicated over 30 years to developing its physics-based computational platform. This decades-long, science-first approach to disrupting one of the world's most complex industries represents a significant "Hard Path" that is difficult and time-consuming for new entrants to replicate.

• Founder-Led with Insider Ownership: The company retains a strong connection to its founding principles. Co-founder Dr. Richard Friesner remains an active board member and consultant, and CEO Dr. Ramy Farid has a long tenure, ensuring continuity of vision. This is augmented by the significant ownership stakes held by sophisticated, long-term investors like the Bill & Melinda Gates Foundation Trust.

• Blend of Technical and Commercial Leadership: The leadership team successfully combines deep scientific expertise at the Ph.D. level with seasoned financial and commercial experience from across the biopharmaceutical industry, providing the balanced perspective needed to navigate both scientific challenges and market realities.

• Key Growth Metrics: The company's financial profile aligns with key high-growth benchmarks.

    ◦ Revenue Growth > 20%: Yes. Total revenue grew 20% year-over-year in fiscal year 2023.

    ◦ Gross Margins > 50%: Yes. The overall gross margin was 71% in fiscal year 2023, driven by the software-specific gross margin of approximately 77%.

Schrödinger clearly exhibits many of the qualitative and quantitative characteristics of a durable, high-growth compounder, but this potential must be weighed against a rigorous analysis of the risks that could derail the thesis.

--------------------------------------------------------------------------------

Part 3: Risk Analysis / Inversion ("Pre-Mortem")

To fully test the investment thesis, this section performs a "pre-mortem" by inverting the analysis. It will rigorously detail the potential failure points and thesis-breakers that could lead to a negative investment outcome over the next five years, drawing directly from the "Risk Factors" disclosed in the company's SEC filings.

• I. Clinical and Pipeline Risks

    ◦ Clinical Trial Failure: This is the most significant and acute risk. The discontinuation of the SGR-2921 program due to treatment-related adverse events is a concrete example that promising preclinical data does not guarantee clinical success. A similar failure in one of the company's lead programs, such as SGR-1505 or SGR-3515, would severely impact the company's valuation and market sentiment.

    ◦ Inability to Achieve Profitability: The company has a history of significant operating losses and negative operating cash flow. While management has pivoted toward financial discipline, failure to execute this strategy could lead to excessive cash burn, eroding the company's strong balance sheet and forcing future dilutive financings at potentially unfavorable terms.

• II. Competitive and Technological Risks

    ◦ Intense Competition: Schrödinger faces competition from multiple vectors: established software providers (e.g., BIOVIA, Certara), academic consortia developing open-source tools (e.g., AMBER, GROMACS), and a rapidly evolving field of venture-backed, AI-driven drug discovery companies.

    ◦ Technological Obsolescence: The field is dynamic. A competitor could develop a superior technology, such as a breakthrough AI or machine learning approach, that renders Schrödinger's physics-based methods less desirable or efficient, eroding its primary competitive advantage.

• III. Commercial and Business Risks

    ◦ Customer Concentration & Industry Headwinds: A significant portion of software revenue comes from life sciences customers. For the year ended December 31, 2023, two customers accounted for 26% and 11% of total revenues, respectively. Industry consolidation, budget cuts, or a slowdown in R&D spending within the biopharma sector could adversely affect software sales and growth.

    ◦ Collaboration Dependence: A portion of revenue and platform validation is dependent on collaborators' decisions to advance programs and make milestone payments. A key partner, such as Bristol-Myers Squibb or Novartis, could choose to terminate a collaboration for strategic or clinical reasons, impacting revenue and perception of the platform's value.

• IV. Regulatory and Macroeconomic Risks

    ◦ Regulatory Hurdles: The company's pipeline is subject to the full spectrum of regulatory risks, including the FDA placing clinical holds on trials, unforeseen safety issues, and challenges in securing marketing approval. Furthermore, changes in drug pricing legislation (e.g., the Inflation Reduction Act) could impact the commercial potential of future products. Evolving data privacy laws like GDPR and CCPA also add to the compliance burden.

    ◦ Geopolitical and Supply Chain Risks: The company relies on foreign contract research organizations (CROs) and contract manufacturing organizations (CMOs). Geopolitical tensions and legislation like the BIOSECURE Act, which targets relationships with certain Chinese biotech companies, could disrupt supply chains and collaborations, leading to delays and increased costs.

These risks are substantial and inherent to the company's business model, underscoring that a positive investment outcome is not guaranteed and depends heavily on continued execution.

--------------------------------------------------------------------------------

Part 4: Scoring Matrix

This final section synthesizes the entire analysis into a quantitative scoring matrix. Each core attribute of the company is scored on a scale of 1 (Awful) to 10 (World-Class), supported by a concise, data-driven justification derived from the preceding analysis.

Leadership & Capital Allocation:

• Score (1-10): 8

• Justification: The team combines deep scientific and financial expertise, evidenced by a board and executive roster with extensive industry experience. Management has demonstrated prudent capital allocation, generating a positive return profile on historical R&D investment ($419M in value from $486M spend) and has recently executed a timely strategic pivot to capital preservation and lower operating expense growth.

Business Model & Moat Strength:

• Score (1-10): 9

• Justification: The synergistic three-pillar business model is a key differentiator, creating a self-funding and self-validating innovation engine. The competitive moat is exceptionally strong, fortified by durable process power (platform validation in approved drugs and monetized transactions) and high switching costs (92%+ retention for key customers).

Financial Strength & ROCE:

• Score (1-10): 7

• Justification: The score reflects a balance between a strong, debt-free balance sheet with high cash and marketable security reserves ($475.2M) and a history of operating losses and negative cash flow. The company's path to profitability is not yet established, but the improving cash burn trajectory guided for 2025 and the high-margin profile of the software segment provide a clear path forward.

Execution & Track Record:

• Score (1-10): 8

• Justification: Management has demonstrated consistent execution against its stated goals. Key achievements include advancing multiple proprietary programs from discovery into the clinic (SGR-1505, SGR-3515), securing and delivering on major collaborations with industry leaders like Novartis, and successfully growing the high-ACV software customer base.

Future Catalysts & Probability:

• Score (1-10): 7

• Justification: The company possesses a dense pipeline of near-term, value-inflecting catalysts, most notably the initial clinical data readouts for SGR-1505 and SGR-3515. However, the score is tempered by the realistic, industry-standard probabilities of clinical success, as exemplified by the SGR-2921 program discontinuation.

Valuation & Margin of Safety:

• Score (1-10): 7

• Justification: The Sum-of-the-Parts analysis suggests the January 2024 market capitalization of $2.3B is substantially covered by the durable software business and net cash. This implies the market is offering the entire high-upside drug discovery pipeline at a significant discount, creating a potential margin of safety for long-term investors.

Overall Score:

• Score (1-10): 7.7

• Justification: Schrödinger represents a high-quality, uniquely positioned enterprise whose world-class technological platform and resilient business model are balanced against the inherent risks of clinical-stage drug development and the ongoing journey toward sustained profitability.

Overall Score 8/10

#### Part 1: Valuing the Software Business 🖥️

Schrödinger's software business is a high-growth, recurring revenue engine. We will value it like a SaaS company, using a multiple of its sales.

Metric Base Case Assumption Justification

Software Revenue (LTM) $190 Million Last Twelve Months revenue from the software segment.

Peer Group EV/Sales Multiple 8.0x A reasonable multiple for a specialized, high-growth software business. Peers in scientific software can trade in a 6x-10x range.

$190 Million (Software Revenue) * 8.0x (EV/Sales Multiple) = $1.52 Billion

Value of Software Business = $1.52 Billion

#### Part 2: Valuing the Drug Pipeline 💊

Next, we value Schrödinger's most advanced internal drug programs using the rNPV method. We will focus on their three key assets.

Metric SGR-1505 (MALT1) SGR-2921 (CDC7) SGR-3515 (Wee1)

Stage Phase 2 Phase 1 Phase 1

Peak Sales Estimate $900 Million $1.2 Billion $1.5 Billion

Probability of Success (POS) 25% (Standard for P2) 12% (Standard for P1) 12% (Standard for P1)

We will use the same general assumptions from our CYTK model: 12% discount rate, 22% FCF margin, 12 years of peak sales.

rNPV Calculations:

SGR-1505 (MALT1): The risk-adjusted NPV is $455 Million.

SGR-2921 (CDC7): The risk-adjusted NPV is $291 Million.

SGR-3515 (Wee1): The risk-adjusted NPV is $364 Million.

Total Pipeline Value:

$455M + $291M + $364M = $1.11 Billion

Value of Drug Pipeline = $1.11 Billion

#### Part 3: Sum-of-the-Parts Calculation

Now, we add the value of the two businesses together and adjust for cash and shares to find the price per share.

Metric Base Case Value

1. Value of Software Business $1.52 Billion

2. Value of Drug Pipeline $1.11 Billion

Total Enterprise Value (1 + 2) $2.63 Billion

Add: Net Cash ~$480 Million

Total Equity Value $3.11 Billion

Divide by: Shares Outstanding ~72 Million

Final Implied Value Per Share ~$43.20 per share